Program
etakafusp alfa
Also written as “AB248” and “etakafusp alfa (AB248)”.
Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 11 open or running | phase 1since Jun 17, 2025 | Jun 17, 2025 | Mar 18, 2028phase 1 · NCT07037758 |
| Asher Biotherapeutics | 11 open or running | phase 1since Nov 30, 2022 | Nov 30, 2022 | none ahead |
Also a collaborator on its studies: Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 30, 2022First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Asher BiotherapeuticsAsher Biotherapeutics · NCT05653882 · 552 enrolled · United States
- Jun 17, 2025Amgen’s first study: phase 1 study in Extensive Stage Small Cell Lung CancerNew to AmgenAmgen · NCT07037758 · 380 planned · United States, South Korea, Turkey (Türkiye)
Ahead
- Mar 18, 2028Primary completion: phase 1 study in Extensive Stage Small Cell Lung CancerAmgen · NCT07037758
TargetBeta
“A recombinant fusion protein comprised of a humanized immunoglobulin G1 (IgG1) antibody targeting the T-cell surface glycoprotein CD8 beta chain (CD8b) ”NCIt, by rule
Other programs on CD8A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
| CD8-guided IL-2 Fusion Protein AZD6750 | AstraZeneca | phase 2 | 1 |
| Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621 | AstraZeneca | phase 2 | 1 |
| Anti-GPC3 T Cell-engaging Antibody AZD9793 | AstraZeneca | phase 2 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07037758Extensive Stage Small Cell Lung Cancer · United States, South Korea, Turkey (Türkiye) | 1 | Recruiting | Amgen | Mar 18, 2028 | 380 |
| NCT05653882Carcinoma, Non-Small-Cell Lung · United States | 1 | Active, not recruiting | Asher Biotherapeutics | Aug 2026 | 552 |
How it is read
Names in the registry
- “AB248”, 1 entry
- “etakafusp alfa (AB248)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.